Skip to main content Go body Go Menu
  • Enterprise
    Samsung Bioepis has begun direct sales of the low-concentration formulation(40 mg/ml) of its ophthalmic disease treatment, OPUVIZ, in Europe. Samsung Bioepis announced that it is targeting a global market worth approximately KRW 12 trillion in annual sales with OPUVIZ, a biosimilar of ‘Eylea’ developed by the U.S. company Regeneron.
광고를 불러오는 중...
[NSPAD]LG그룹
[NSPAD]삼성전자
G01 광고를 불러오는 중...